Application of garter snake antipruritic pill in preparation of medicine for preventing and treating pathological skin water shortage

Abstract

The invention relates to a novel application of garter snake antipruritic pills. According to the invention, an animal model is established by smearing a 1-chloro-2, 4-dinitrobenzene inducer, and based on the model, the effect of the garter snake antipruritic pill in improvement of dermatitis degree, histopathological injury, skin moisture content and lymphocyte subpopulation Th1 / Th2 proportion is verified; the application of the traditional Chinese medicine composition in preparation of medicines for preventing and treating pathological skin water shortage, medicines for recovering immune functions or medicines for preventing and treating atopic dermatitis is proved.

Description

Technical Field

[0001] The invention relates to the field of biomedicine, and specifically to a new application of Wushe Zhiyang Pills, and particularly to an application of the Wushe Zhiyang Pills in preparing a medicine for preventing and treating pathological skin dehydration, a medicine for restoring immune function, or a medicine for preventing and treating atopic dermatitis. Background Art

[0002] Wushe Zhiyang Pills are composed of black-striped snake (fried with white wine), Saposhnikovia divaricata, Cnidium monnieri, Sophora flavescens, Phellodendron chinense, Atractylodes macrocephala (soaked), red ginseng root, Paeonia suffruticosa, snake bile, artificial bezoar, and Chinese angelica. They have the effects of nourishing blood, dispelling wind, drying dampness and relieving itching. The standard is included in the Pharmacopoeia of the People's Republic of China. Modern pharmacological studies have shown that Wushe Zhiyang Pills have antipruritic, anti-allergic and anti-inflammatory effects. They are clinically used to treat common skin diseases such as urticaria and pruritus. Whether Wushe Zhiyang Pills have other clinical uses remains to be studied. Summary of the invention

[0003] The main purpose of the embodiments of the present application includes providing a new application of Wushe Zhiyang Pills, including the following technical solutions:

[0004] In a first aspect of the present application, there is provided a use of Wushe Zhiyang Pills in the preparation of a medicament for preventing and treating pathological skin dehydration.

[0005] In some embodiments of the present application, an effective dose of the drug significantly increases the skin moisture content of the subject.

[0006] In some embodiments of the present application, the pathological skin dehydration includes skin dehydration caused by inflammation.

[0007] In some embodiments of the present application, the inflammation comprises dermatitis.

[0008] In some embodiments of the present application, the subject of the drug is a mammal.

[0009] In some embodiments of the present application, the mammal is a primate.

[0010] In some embodiments of the present application, the primate includes humans or mice.

[0011] In the second aspect of the present application, there is provided the use of Wushe Zhiyang Pills in the preparation of immune function recovery drugs.

[0012] In some embodiments of the present application, an effective dose of the drug significantly increases the Th1 / Th2 ratio of lymphocyte subpopulations in the subject.

[0013] In some embodiments of the present application, the subject of the drug is a mammal.

[0014] In some embodiments of the present application, the mammal is a primate.

[0015] In some embodiments of the present application, the primate includes humans or mice.

[0016] In the third aspect of the present application, there is provided the use of Wushe Zhiyang Pills in the preparation of a medicament for preventing and treating atopic dermatitis.

[0017] In some embodiments of the present application, the subject of the drug is a mammal.

[0018] In some embodiments of the present application, the mammal is a primate.

[0019] In some embodiments of the present application, the primate includes humans or mice.

[0020] The details of one or more embodiments of the present application are set forth in the description which follows, and other features, objects, and advantages of the present application will be apparent from the description and its claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative work.

[0022] Figure 1 Wushe Zhiyang Pills improved the dermatitis score of mice;

[0023] Figure 2 Wushe Zhiyang Pills improves the skin moisture content of mice;

[0024] Figure 3 Wushe Zhiyang Pills improves atopic dermatitis-like pathological changes in mice;

[0025] Figure 4 Wushe Zhiyang Pills improves the expression of inflammatory factors in mice;

[0026] Figure 5 Wushe Zhiyang Pills improve the Th1 / Th2 ratio of spleen lymphocyte subsets in mice. DETAILED DESCRIPTION

[0027] The present invention will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present invention more thorough and comprehensive. It should also be understood that the present invention can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various changes or modifications without violating the connotation of the present invention, and the equivalent form obtained also falls within the protection scope of the present application. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present invention. It should be understood that the present invention can be implemented without one or more of these details.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing implementation modes and embodiments and are not intended to limit the present invention.

[0029] the term

[0030] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0031] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0032] In the present invention, "plurality", "multiple", "multiple times", "multiple" and the like, unless otherwise specified, refer to a number greater than or equal to 2. For example, "one or more" means one or greater than or equal to two.

[0033] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.

[0034] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of the present invention, solve the technical problem of the present invention, and achieve the expected technical effect of the present invention.

[0035] Herein, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of the present invention.

[0036] Herein, “further”, “furthermore”, “particularly”, etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present invention.

[0037] In this article, "optionally", "optional", and "optional" mean optional, that is, any one of the two parallel options of "yes" or "no". If there are multiple "options" in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "option" is independent.

[0038] In this document, the terms "first", "second", "third", "fourth", etc. in "the first aspect", "the second aspect", "the third aspect", "the fourth aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0039] In this article, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0040] Herein, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when a numerical interval only refers to integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all sub-ranges included therein.

[0041] The temperature parameters herein, if not specifically limited, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0042] Herein, %(w / w) and wt% both refer to weight percentage, %(v / v) refers to volume percentage, and %(w / v) refers to mass volume percentage.

[0043] The first aspect of the present application

[0044] The present application provides the use of Wushe Zhiyang Pills in the preparation of a medicine for preventing and treating pathological skin dehydration.

[0045] In one example of the present application, the drug significantly increases the skin moisture content of the subject.

[0046] In one example of the present application, the pathological skin dehydration includes skin dehydration caused by inflammation.

[0047] In one example of the present application, the inflammation includes dermatitis.

[0048] The second aspect of the present application

[0049] The present application provides the use of Wushe Zhiyang Pills in the preparation of immune function recovery drugs.

[0050] In one example of the present application, the drug significantly increases the ratio of lymphocyte subpopulations Th1 / Th2 in the body.

[0051] The third aspect of the present application

[0052] The present application provides the use of Wushe Zhiyang Pills in the preparation of a medicament for preventing and treating atopic dermatitis.

[0053] Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with the main clinical features of dry and itchy skin. The pathogenesis of atopic dermatitis is complex and is closely related to factors such as skin barrier dysfunction, immune abnormalities, skin flora disorders, and family inheritance. At present, the treatment of atopic dermatitis mainly uses glucocorticoids, antihistamines, and immunosuppressants. Although these therapies can relieve clinical symptoms to a certain extent, these drugs only treat the symptoms and not the root cause, and long-term use is prone to a series of adverse reactions. For example, long-term use of hormone drugs can cause thinning of the skin, accelerated rupture and bleeding; immunosuppressants can damage the liver and kidneys. Therefore, finding drugs to improve and relieve atopic dermatitis is of great clinical significance in the prevention and treatment of atopic dermatitis.

[0054] According to traditional Chinese medicine, AD is caused by the combination of internal and external evils. The internal causes are spleen deficiency, stomach heat, spleen and lung qi deficiency, and hyperactivity of heart fire. The external causes are wind, dampness, and heat. The skin is affected by wind, dampness, and heat. Over time, it turns into heat, and dampness and heat accumulate in the skin pores and cause the disease. The treatment principles are mostly to strengthen the spleen and eliminate dampness, clear heat and cool blood, promote blood circulation and remove blood stasis, and eliminate wind and stop itching. Traditional Chinese medicine has a long history of preventing and treating AD, with outstanding efficacy and few adverse reactions. With the increasing attention paid to traditional Chinese medicine around the world, traditional Chinese medicine has been widely recognized for preventing and treating atopic dermatitis. However, so far, no clear data has been found to show the application of Wushe Zhiyang Pills in atopic dermatitis.

[0055] The purpose of this application is to provide the use of Wushe Zhiyang Pills in drugs for alleviating atopic dermatitis, thereby further increasing the indications of Wushe Zhiyang Pills and providing a new drug option for the treatment of patients with atopic dermatitis.

[0056] The present application proves that Wushe Zhiyang Pills have the effect of relieving atopic dermatitis through in vivo animal experiments. This effect was confirmed in an atopic dermatitis animal experimental model established by applying 1-chloro-2,4-dinitrobenzene inducer. When we evaluated the effect of Wushe Zhiyang Pills on the protective effect of atopic dermatitis disease, we found that Wushe Zhiyang Pills can improve the degree of dermatitis and tissue pathological damage in animals with atopic dermatitis disease, and improve the skin water content and lymphocyte subset Th1 / Th2 ratio of animals with atopic dermatitis disease. Based on the above results, the new use of Wushe Zhiyang Pills described in the present invention is confirmed.

[0057] As used herein, "prevention" and "prevention and / or treatment" have the same meaning and can be used interchangeably. In the present invention, "prevention" includes aspects such as prevention, treatment, and adjuvant therapy. As used herein, "prevention" means to alleviate, slow the progression, attenuate, prevent, or maintain an existing disease or condition. "Prevention" also includes curing, preventing the development of, or alleviating to a certain extent, one or more symptoms of a disease or condition.

[0058] Herein, "effective dose" will vary according to the specific state, disease, disorder or condition and its severity for treatment, as well as the age, weight, physical condition and responsiveness of the individual being treated. Therefore, one or more of these parameters can be used to select and adjust the therapeutically effective amount of Wushe Zhiyang Pills.

[0059] Herein, in the present invention, "subject" refers to a patient taking a drug.

[0060] Herein, "subject" is an animal, preferably a mammal, more preferably a human, and the subject includes but is not limited to a patient with a disease, illness and / or symptom. The subject in the present invention is preferably a mammal. The term "mammal" mainly refers to warm-blooded vertebrate mammals, including but not limited to: such as cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats, mice), pigs, cattle, sheep, horses, humans, etc., preferably primates, more preferably humans.

[0061] Herein, the dosage form of the drug is not particularly limited, including but not limited to pills.

[0062] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0063] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0064] Example 1

[0065] 1. Experimental Methods

[0066] (1) Establishment of animal model and drug intervention

[0067] After one week of adaptive feeding, male BALB / c mice (6-8 weeks old, 20±2g, SPF grade) were randomly divided into 5 groups: normal control group (Control), model control group (DNCB), Wushe Zhiyang Pills low-dose group (WSL, 3.075g / kg), Wushe Zhiyang Pills high-dose group (WSH, 6.150g / kg), and positive drug dexamethasone group (DEX), with 15 mice in each group.

[0068] The mice underwent back hair removal, and were sensitized with 1wt% DNCB on the 0th and 4th days (DNCB was dissolved in a mixture of acetone and olive oil, ratio 3:1, v:v) on the back hair removal area and right ear of the mice. On days 8-30, the same volume of 0.6wt% DNCB was used to repeatedly stimulate the back hair removal area and right ear of the mice, once every two days. The control group used an equal volume of acetone and olive oil mixture dripped on the back hair removal area and right ear of the mice as a blank control.

[0069] The mice in the WSL and WSH groups were gavaged with Wushe Zhiyang Pills (3.075 g / kg / d and 6.150 g / kg / d) every day, and the mice in the DEX group were gavaged with dexamethasone (2 mg / kg / d). The mice in the Control and DNCB groups were gavaged with an equal volume of distilled water.

[0070] (2) Detection of changes in mouse skin dermatitis scores (SCOR atopic dermatitis)

[0071] The dermatitis score of the hair loss area on the back of mice 1 hour after modeling on the 22nd day was scored by referring to the index in the Clinical Atopic Dermatitis Scoring Rating (SCOR Atopic Dermatitis) scale. It was mainly defined as the sum of four symptoms: hemorrhage / erythema, edema / papule, epidermal exfoliation / scratches, and scaling / erosion, which were divided into 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The total dermatitis score ranged from 0 to 12 points. The higher the score, the more severe the skin damage.

[0072] (3) Detection of changes in mouse skin water content

[0073] On the 0th and 8th days, the skin moisture content was tested with a skin moisture tester. Three dorsal skin hair removal sites were randomly selected and tested under controlled conditions (23±3°C, 55±5% humidity). Finally, the average value of the three skin moisture measurements was taken.

[0074] (4) Detection of pathological changes in mouse skin

[0075] Hematoxylin-eosin staining (H&E staining) and toluidine blue staining (TB staining) were used to detect the changes in epidermal thickness and mast cell infiltration in the skin of each group of mice.

[0076] First, the skin sections were dewaxed, placed in xylene twice, 10 minutes each time, and then placed in gradient alcohol for 5 minutes each for hydration and rinsed for 2 minutes. HE staining and TB staining were performed separately, and the excess dye was washed off and placed in gradient alcohol for 5 minutes each for dehydration. Xylene was transparent, dried, and sealed with neutral resin, sealed with colorless transparent nail polish, and stored after drying. Microscopic examination showed that the nucleus of the HE skin sections was blue-purple, the cytoplasm was pink, the mast cells were purple-blue, and the background was light blue. Image acquisition and analysis were performed, and Image J software was used to determine the thickness of the skin epidermis and observe and count the number of mast cells.

[0077] (5) ELISA kit to detect changes in total IgE in mouse serum

[0078] Strictly follow the ELISA kit operation, add gradient dilution standard solution and the sample to be tested to the reaction well, incubate at room temperature for 2h, wash 4 times, add detection antibody, incubate at room temperature for 2h, wash 4 times, add avidin peroxidase, incubate at room temperature in the dark for 20min, wash 4 times, add TMB substrate solution, incubate at room temperature in the dark for 20min, add stop solution after color reaction, quickly place in the microplate reader to detect absorbance, detect OD value at 450nm and 570 wavelength, calibrate OD value, then establish a standard curve, and calculate sample concentration.

[0079] (6) Real-time fluorescence quantitative PCR detection of changes in inflammatory factors in mouse skin

[0080] Real-time fluorescence quantitative PCR was used to determine the level of IL-4 inflammatory gene produced by Th2 in the skin tissue of atopic dermatitis mice. An appropriate amount of skin tissue was taken for grinding and lysis, RNA was extracted, RNA was reverse transcribed into cDNA, and the reaction components were added to the PCR plate, placed in the PCR instrument, and the program was set for amplification. The data was recorded, the template amount was calculated, and the results were analyzed. The expression of IL-4 in the skin tissue modeling of each group of mice was analyzed.

[0081] (7) Flow cytometry detection of changes in immune cells (Th1 / Th2 ratio) in mouse spleen

[0082] The spleen was ground and passed through a 70 μm cell sieve, centrifuged and the supernatant was discarded, red blood cells were lysed, and lymphocyte suspension was obtained after centrifugation. The cells were incubated and stimulated with PMA, ionomycin, BFA, and monensin for 5 h, washed with PBS, centrifuged and the supernatant was discarded, CD3+ and CD4+ antibodies were added for surface staining, incubated at 4°C in the dark for 15 min, the precipitate was washed with PBS, the supernatant was discarded by centrifugation, the fixation / permeabilization solution was added, fixed at 4°C in the dark for 45 min, the precipitate was washed with permeabilization buffer, the supernatant was discarded by centrifugation, IFN-γ and IL-4 antibodies were added for intracellular staining, incubated at 4°C in the dark overnight, the precipitate was washed with permeabilization buffer, the supernatant was discarded by centrifugation, the cells were resuspended with PBS, and the flow cytometer was used for detection. The detection results were analyzed using flowjo software.

[0083] (8) Data Statistical Analysis

[0084] The experimental results were expressed as mean ± SEM. Graphpad Prism9 software was used to perform statistical analysis on the experimental data. One-way ANOVA was used for inter-group comparisons. p < 0.05 indicated a significant difference.

[0085] 2. Experimental results

[0086] (1) Wushe Zhiyang Pills improve the dermatitis score of mice

[0087] Figure 1 .Wushe Zhiyang Pills improved the dermatitis score of mice. Figure A is a representative picture of atopic dermatitis-like pathological changes on the back of mice on the 22nd day of modeling; Figure B is the change in dermatitis score on the 22nd day of modeling. Compared with the normal group, ### p<0.001 was significantly different; compared with the DNCB group, *** There was a significant difference when p<0.001 (n=15).

[0088] like Figure 1 As shown in Figure 2, compared with the normal control group, the mice in the DNCB group developed atopic dermatitis-like pathological changes such as ulceration, redness, swelling, and epidermal exfoliation on the 22nd day, and the dermatitis score was significantly increased (p ### <0.001). Compared with the DNCB group, administration of low-dose and high-dose Wushe Zhiyang Pills and dexamethasone significantly improved dermatitis symptoms and reduced dermatitis scores (p***<0.001).

[0089] (2) Wushe Zhiyang Pills improve the skin moisture content of mice

[0090] Figure 2 .Wushe Zhiyang Pills improved the skin moisture content of mice. On the 0th and 8th days, the skin moisture content of each group of mice at the modeling site was measured using a skin moisture tester. Compared with the normal group, ###p<0.001, there is a significant difference; compared with the DNCB group, ***p<0.001, there is a significant difference (n=15).

[0091] like Figure 2 As shown in Figure 2, compared with the normal control group, the skin water content of mice in the DNCB group was significantly reduced on day 8 (p ### <0.001). Compared with the DNCB group, low and high doses of Wushe Zhiyang Pills and dexamethasone could significantly increase the skin water content of mice (p *** <0.001).

[0092] Table 1

[0093] Control Group DNCB group WSL Group WSH Group DEX Group Day 0 62.89±2.01 59.70±3.52 62.03±2.95 59.64±3.87 63.24±3.04 Day 8 43.08±2.19 22.70±4.54 29.78±5.21 31.08±4.97 19.81±6.56

[0094] Note: Data are presented as mean±SD, and one-way ANOVA was used. Compared with the normal group, p###<0.001 showed significant difference; compared with the DNCB group, p**<0.01, p***<0.001 showed significant difference.

[0095] (3) Wushe Zhiyang Pills improve atopic dermatitis-like pathological changes in mice

[0096] Figure 3 .Wushe Zhiyang Pills improve the pathological changes of atopic dermatitis in mice. Figure A is a representative picture of H&E staining and TB staining of skin sections at the modeling site of each group of mice; Figure B is a statistical chart of changes in skin epidermal thickness of each group of mice (n=3); Figure C is a statistical chart of changes in the number of mast cells of each group of mice (n=4). Compared with the normal group, ### p<0.001 was significantly different; compared with the DNCB group, ** There is a significant difference when p<0.001.

[0097] like Figure 3 As shown in the figure, compared with the normal control group, the skin epidermis of mice in the DNCB group was significantly thickened (p ### <0.001), the number of mast cells increased significantly (p ### <0.001), and skin pathology showed atopic dermatitis-related manifestations. Compared with the DNCB group, low and high doses of Wushe Zhiyang Pills and dexamethasone significantly reduced the thickness of the skin epidermis (p ** <0.001), significantly reduced the number of mast cells (p ** <0.001), significantly improving atopic dermatitis-like pathological changes.

[0098] (4) Wushe Zhiyang Pills improve the expression of inflammatory factors in mice

[0099] Figure 4.Wushe Zhiyang Pills improve the expression of inflammatory factors in mice. Figure A shows the changes in the total IgE content in the serum of each group of mice (n=8); Figure B shows the changes in the expression of IL-4 inflammatory factors in the skin of each group of mice (n=5). Compared with the normal group, ### p<0.001, there is a significant difference; compared with the DNCB group, ***p<0.001, there is a significant difference.

[0100] like Figure 4 As shown in Figure 2, compared with the normal control group, the total IgE content in the serum of mice in the DNCB group was significantly increased (p ### <0.001, and the expression of IL-4 inflammatory factor in the skin increased significantly (p ### <0.001). Compared with the DNCB group, low and high doses of Wushe Zhiyang Pills and dexamethasone significantly reduced the total IgE content in the serum of mice (p *** <0.001, and significantly reduced the expression of IL-4 inflammatory factor in the skin (p *** <0.001).

[0101] (5) Wushe Zhiyang Pills improve the Th1 / Th2 ratio of spleen immune cells in mice

[0102] like Figure 5 As shown in Figure 2, compared with the normal control group, the ratio of Th1 / Th2 lymphocyte subsets in the spleen of mice in the DNCB group was significantly decreased (p ### <0.001), there is immune dysfunction, leading to the occurrence of atopic dermatitis. Compared with the DNCB group, low and high doses of Wushe Zhiyang Pills and dexamethasone can significantly increase the ratio of Th1 / Th2 lymphocyte subsets in the spleen ( * p<0.05, ** p<0.01), restoring the immune function of mice to balance.

[0103] Figure 5 .Wushe Zhiyang Pills improve the Th1 / Th2 ratio of spleen lymphocyte subsets in mice. Figure A is a representative graph of the Th1 / Th2 ratio of spleen lymphocyte subsets in each group of mice; Figure B is a statistical graph of the changes in the Th1 / Th2 ratio of spleen lymphocyte subsets in each group of mice. Compared with the normal group, ### p<0.001 was significantly different; compared with the DNCB group, * p<0.05, ** There was a significant difference when p<0.01 (n=7-8).

[0104] 3. Experimental results

[0105] The above experimental results show that Wushe Zhiyang Pills can significantly relieve the symptoms of pathological skin dehydration and provide a new drug option for the clinical treatment of atopic dermatitis and improvement of immune function.

[0106] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0107] The above-described embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solutions of the present invention in detail, but cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present invention, several variations and improvements can be made, which all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of this application. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solutions provided by the present invention through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description and drawings can be used to explain the contents of the claims.

Claims

1. Application of Wushe Zhiyang Pills in the preparation of medicines for preventing and treating pathological skin dehydration.

2. The use according to claim 1, characterized in that: An effective dose of the drug significantly increases the skin moisture content of the subject.

3. The use according to claim 1 or 2, characterized in that: The pathological skin dehydration includes skin dehydration caused by inflammation.

4. The use according to claim 3, characterized in that: The inflammation includes dermatitis.

5. Application of Wushe Zhiyang Pills in the preparation of immune function restoration drugs.

6. The use according to claim 5, characterized in that: An effective dose of the drug significantly increases the Th1 / Th2 ratio of lymphocyte subsets in the subject.

7. Application of Wushe Zhiyang Pills in the preparation of medicines for preventing and treating atopic dermatitis.

8. The use according to any one of claims 1 to 7, characterized in that The subject of the drug is a mammal.

9. The use according to claim 8, characterized in that: The mammal is a primate.

10. The use according to claim 9, characterized in that: The primates include humans or mice.

Images